Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Action Drives Ranbaxy Into Red; Company May Buyout Manufacturing Sites To Recover Lost Ground

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's largest drug maker Ranbaxy suffered heavy losses during its third quarter primarily due to U.S. FDA action in September that clamped an import ban on over 30 of its products

You may also be interested in...



U.S. FDA To Open India Office In December

NEW DELHI - U.S. FDA plans to step up scrutiny of drugs and food made in India for the U.S. market by setting up offices next month in the country after establishing three branches in China, according to U.S. officials

U.S. FDA To Open India Office In December

NEW DELHI - U.S. FDA plans to step up scrutiny of drugs and food made in India for the U.S. market by setting up offices next month in the country after establishing three branches in China, according to U.S. officials

After Ranbaxy, U.S. FDA Hauls Up Caraco Pharma for QC Issues; May Withhold Future Drug Approvals

MUMBAI - U.S. FDA issued a warning letter to Caraco Pharmaceuticals, a subsidiary of India's Sun Pharmaceuticals, after the drug regulator found quality control lapses at its Detroit facilities, Curaco announced Nov. 3. U.S. FDA said the QC lapses conflicted with the company's standard operating procedures

Related Content

UsernamePublicRestriction

Register

SC067045

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel